Tigloylgomisin H significantly induces quinone reductase (QR) activity in Hepa1c1c7 mouse hepatocarcinoma cells. Tigloylgomisin H functions as a novel monofunctional inducer that specifically upregulates phase II enzymes through the Nrf2-ARE pathway and can be used in liver cancer prevention studies.